share_log

ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024

ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024

ALT5 Sigma報告,2024年7月交易成交量同比增長114%
Accesswire ·  08/13 08:30

LAS VEGAS, NV / ACCESSWIRE / August 13, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for July 2024.

ALT5 Sigma公司(NASDAQ: ALTS)是一家金融科技公司,提供下一代基於區塊鏈技術的數字資產代幣化、交易、清算、結算、支付和保管等服務。該公司宣佈公佈2024年7月的交易額,爲1.795億美元,同比增長114%,高於2023年7月的8400萬美元。ALT5年至今的交易額爲10.5億美元,同比增長101%。

According to the company, ALT5's transaction volume exceeded US$179 million for the month of July 2024, which represents a year-over-year increase of 114% from the $84 million recorded in July 2023. ALT5's year-to-date transaction volume is $1.05 billion, which represents a year-over-year increase of 101%.

ALT5公司表示,截至2024年7月,ALT5的交易額超過1.79億美元,同比增長114%,高於2023年7月的8400萬美元。ALT5年至今的交易額爲10.5億美元,同比增長101%。

July 2024

July 2023

July 2022

July 2021

$179,352,052

$83,810,993

$47,264,497

$26,582,621

2024年7月

2023年7月

2022年7月

2021年7月

1.79352052億美元

8381.0993萬美元

4726.4497萬美元

2658.2621萬美元

"Based on historical seasonality that we have experienced over the last few years, the second half of the fiscal year traditionally sees an uptick in transaction volume. We are pleased with the year-over-year growth and encouraged by the month-over-month increase in business as well," said Vay Tham, Chief Revenue Officer of ALT5 Sigma Corporation. "We continue to focus on growth and providing our solutions to an expanding set of organizations in our core markets," further added Mr. Tham.

「基於我們在過去幾年中所經歷的歷史季節性趨勢,財年的下半年通常會看到交易量的上升。我們對同比增長感到高興,並對業務的逐月增長感到鼓舞,」ALT5 Sigma公司的首席營收官Vay Tham說道。「我們繼續專注於增長,並向我們的核心市場中越來越多的組織提供解決方案,」Tham先生補充道。

About ALT5 Sigma

關於ALT5 Sigma

The Company is a unique Nasdaq-listed multidisciplinary organization with a focus on healthcare and fintech. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.

該公司是一家獨特的納斯達克上市的多學科組織,專注於醫療保健和金融科技。截至2024年6月28日,該公司是羅素微型股指數的成分股之一。

Launched in 2018, ALT5 Sigma Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma Inc., through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime". ALT5 Sigma Inc. processed over US$1.2 billion in cryptocurrency transactions in 2023.

ALT5 Sigma Inc.成立於2018年,是 ALT5 Sigma Corporation 的全資子公司,是一家提供區塊鏈技術的金融科技公司,以實現遷移到一個新的全球金融範式爲目標。ALT5 Sigma Inc.通過其子公司向客戶提供兩個主要平台:「ALT5 Pay」和「ALT5 Prime」。ALT5 Sigma Inc.在2023年的加密貨幣交易額超過12億美元。

ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (s) automatically or to receive their payment in digital assets.

ALT5 Pay是一種加密貨幣支付網關,可以使全球註冊和批准的商家接受和進行加密貨幣支付,或使用WooCommerce的插件或ALT5 Pay的結帳小部件和API集成ALT5 Pay支付平台到其應用程序或操作中。商家可以選擇自動轉換成法定貨幣或以數字資產接收付款。

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.

ALT5 Prime是一種電子場外交易平台,允許註冊和批准的客戶買賣數字資產。客戶可以使用法定貨幣購買數字資產,同樣,客戶也可以出售數字資產並獲得法定貨幣。ALT5 Prime可通過一個名爲「ALT5 Pro」的基於瀏覽器的移動應用程序使用,該應用程序可從Apple App Store、Google Play、ALT5 Prime的FIX API以及Broadridge Financial Solutions的NYFIX網關中下載,並提供給批准的客戶。

Through its biotech activities, the Company is developing innovative, actionable solutions intended to help end the opioid crisis. The Company is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

通過其生物科技業務,公司正在開發創新的、切實可行的解決方案,以幫助終結鴉片危機。該公司致力於向創新、技術和教育方面提供資金,以尋找國家歷史上最致命和最普遍的鴉片流行病的關鍵解決方案。該公司在臨床試驗流水線中的藥物已經顯示出有希望將針對疼痛原因的創新治療作爲對不願暴露於上癮的鴉片類藥物的患者的一種戰略性選擇。

Forward Looking Statements

前瞻性聲明

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also contains statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

本新聞稿包含作爲1995年《私人證券訴訟改革法》定義的前瞻性陳述,包括但不限於涉及ALT5平台和業務的盈利能力和前景的聲明,可能包括但不限於國際貨幣風險、第三方或客戶信用風險、源於ALT5服務的責任索賠和未來增長或擴張的技術挑戰。本新聞稿還包含涉及JAN 101將治療PAD、JAN 123將治療CRPS、臨床試驗開始時間、FDA將允許通過505(b)(2)途徑批准JAN 123、獲批後JAN 101將立即顛覆PAD市場以及其他聲明,包括"繼續"、"期望"、"打算"、"將"、"希望"、"應該"、"將"、"可能"、"潛在"等類似表述。這些陳述反映了公司對未來事件的當前看法,受到風險和不確定性的影響,必須基於公司認爲合理但固有的業務、經濟、競爭、政治和社會不確定性和 contingencies 的估計和假設。

Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

許多因素可能導致公司的實際結果、績效或成就與本新聞稿所描述的任何未來結果、績效或成就有實質性不同。這些因素可能包括公司在美國證券交易委員會(SEC)提交的定期報告中詳細描述的那些因素。如果其中一個或多個風險或不確定性成爲現實,或者在公司提交給SEC的文件中「風險因素」部分所列的假設被證明不正確,實際結果可能與此處所述有所不同。這些前瞻性陳述是基於本新聞稿的日期進行的,公司無意義且無義務更新這些前瞻性陳述,除非法律要求。公司無法保證這些陳述將證明是準確的,因爲實際結果和未來事件可能會與其中預期的有所不同。由於前瞻性陳述具有固有的不確定性,因此警告個人不要因難以確定的不確定性而對前瞻性陳述產生過度的依賴。

Media Contact Investor Relations

媒體聯繫投資者關係

IR@alt5sigma.com
1-800-400-2247
Contact Information

IR@alt5sigma.com
1-800-400-2247
聯繫信息

Investor Relations
Investor Relations
ir@alt5sigma.com
1-800-400-2247

投資者關係
投資者關係
ir@alt5sigma.com
1-800-400-2247

SOURCE: ALT 5 Sigma Corp.

SOURCE: ALT 5 Sigma Corp.


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論